BioStock: Alligator’s CEO: “We are not surprised by the positive readout”

Lund-based Alligator Bioscience continue to strengthen the case for their phase II candidate mitazalimab with 24-months data. BioStock reached out to CEO Søren Bregenholt to get his comments on the updated data.
– These results align well with our expectations and further reinforce our confidence in mitazalimab’s potential, says Bregenholt.

Read the full article at biostock.se:

Alligator's CEO: "We are not surprised by the positive readout"

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se